Year: 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones. The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to expire at 5:00 p.m., Eastern Time, on November 28, 2022. All other terms and conditions of the tender offer remain unchanged during the extension...

Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray WARREN, N.J., Nov. 29, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today the publication of a crossover food effect pharmacokinetic study of diazepam nasal spray in the peer-reviewed scientific journal Epilepsia. The study was sponsored by Aquestive in 2021 and conducted by an accredited independent clinical research organization. It was included by Aquestive as part of its New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film that was submitted to the U.S. Food & Drug Administration (FDA). The randomized, open-label...

LAS VEGAS, Nov. 29, 2022 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that it has finalized the terms of a historic and long-term processing and production agreement for a large-scale gold and silver ore stockpile in Etzatlan, Jalisco, Mexico. AABB management is thrilled to release the news of this milestone event for the Company to it’s shareholder base and further details will be announced next week. The new gold and silver production project is expected to be the largest high-yield asset addition for the Company’s to date in its strategic expansion initiative to acquire gold production and increase the AABB’s physical gold holdings. About Asia Broadband Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals,...

LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that it has commenced patient studies of its proprietary metabolic health program, Miboko, with the National Health Service (NHS) in the United Kingdom. Miboko, is the first metabolic tracking program to integrate a non-invasive glucose sensor with a lifestyle app that includes recording of food and drink, educational content, and an analytics platform. The program gives the user a metabolic score based on diet, exercise, and the user’s individual glucose response to their food intake. Users are given personalized recommendations...

NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the appointment of Amanda Morgan as Senior Vice President, Commercial. Ms. Morgan will report to Paul Blanchfield, Lantheus’ Chief Operating Officer, and will be responsible for leading all of the Company’s commercial activities, including Sales, Marketing, and Market Access. “I am pleased to welcome Amanda to Lantheus,” said Paul Blanchfield. “Amanda has strong commercial expertise and is an exceptional leader of people and culture. I am confident in her ability to lead our commercial organization and ensure we continue...

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (“VST” or the “Company“) is pleased to announce that, further to its news release dated July 13, 2022, the reverse takeover transaction (the “Transaction“) pursuant to a merger agreement dated effective July 12, 2022, as amended (the “Merger Agreement“), between the Company, IV Hydreight Inc. (“Hydreight“), Hydreight Technologies Inc. (formerly Perihelion Capital Ltd.) (“NURS“), 1362795 B.C. Ltd. (“AssetCo“), and 1203500 B.C. Ltd., a wholly-owned subsidiary of NURS, has completed. Effective November 25, 2022, as a condition to the completion...

Figure 1 DrillingVANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) — NINE MILE METALS LTD. (CSE: NINE, OTCQB: VMSXF, FSE: KQ9) (the “Company” or “Nine Mile”) is pleased to announce that drilling will start on its Nine Mile Brook VMS project on Sunday, December 4, 2022. Nine Mile has secured a track mounted deep drilling rig capable of a depth of 1,000 meters from Lantech Drilling in Dieppe, NB. The drill rig is now on-site and is being prepped for the upcoming program. This is the same drilling partner from our highly successful stage 1 lens area drill program. We will utilize (2) 12-hour drill crews, producing a 24hr drill program field team. This will achieve our exploration program goals quicker, more cost effective and allow our assays to be submitted to the Certified Lab much sooner. Lantech Drilling will be utilizing...

All amounts are stated in United States dollars unless otherwise indicated TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Terra Firma Capital Corporation (TSX-V: TII) (“Terra Firma” or the “Company”), a real estate finance company, today announced its financial results for the three and nine-month periods ended September 30, 2022. Q3 2022 Financial Highlights:Total Assets of $142.6 million Total Investments (a supplementary financial measure)(4) of $122.5 million Total Assets under management (“AUM”, a non-IFRS financial measure) (3) of $128.6 million Future funding commitments of $125.2 million Book Value per share increased by 1.0% to $7.91 (CA$10.94, translated to CA$ using the exchange rate of $1.3829) per share CA$0.06 per share paid in dividends Total Revenue decreased by 11.3% to $3.7 million Net income and comprehensive income...

HeadlinesDelivered strong full fiscal new bookings at $684M, up 16% year over year Record fiscal year revenue for Professional Services Awarded strategic win-back program from big tech Cerence technology in 51% of global auto productionBURLINGTON, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its fourth quarter and fiscal year 2022 results for the year ended September 30, 2022. Results Summary (1) (in millions, except per share data)    Three Months Ended     Twelve Months Ended      September 30,     September 30,      2022     2021     2022     2021  GAAP revenue     $58.1       $98.1       $327.9       $387.2  GAAP gross margin       58.1 %       75.4 %       70.4 %       73.9 %Non-GAAP gross margin       58.9 %       78.1 %       72.4 %       77.3 %GAAP...

NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.    The Annual Meeting of Stockholders and webcast can be accessed via www.virtualshareholdermeeting.com/GALT2022. Please log in approximately 10 minutes before the event to ensure a timely connection. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based...